在制药产业中,仿制是一种被允许的普遍做法,当获得专利保护的药——原研药,在其专利保护期到期后,其他制药企业便可使用原研药的化学合成物专利,合法生产相应的仿制药品。而仿制药在剂型、规格、给药途径、质量以及效力和适应症方面,都应与其原研药相同是目前医药界对仿制药的共识。目前,我国医药市场八成以上为仿制药,如此规模下的仿制药市场却屡屡传来“我国仿制药疗效与原研药相差甚远”等类似声音。那么,究竟我国的仿制药水平如何?仿制药是否真如传言,只是安全 In the pharmaceutical industry, imitation is a permissible general rule. When a patent-protected drug, the original drug, expires after the patent protection period expires, other pharmaceutical companies can use the patent of the chemical compound of the original drug, which is legal Production of generic drugs. The generic drugs in the dosage form, specifications, route of administration, quality and efficacy and indications, should be the same as its original drug is currently the pharmaceutical industry consensus on generic drugs. At present, over 80% of China’s pharmaceutical market is a generic drug, and the generic drug market under such a scale has repeatedly reported “a similar difference between China’s generic drug efficacy and the original drug drug”. So, what is the level of generic drugs in our country? Is it true that generic drugs are just rumors